# VS-7375 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vs-7375

> The FDA approved VS-7375, sponsored by Verastem, Inc. (VSTM), on Jan 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VS-7375 |
| Codes | VS-7375, GFH375 |
| Sponsor | Verastem, Inc. (VSTM) https://sec-api.dev/companies/vstm/catalysts |
| Indications | advanced kras g12d mutant solid tumors, advanced, [Pancreatic Ductal Adenocarcinoma (PDAC)](https://sec-api.dev/indications/pancreatic-ductal-adenocarcinoma-pdac), [Non-Small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer), [Colorectal Cancer](https://sec-api.dev/indications/colorectal-cancer) |
| Modality |  |
| FDA designations | breakthrough, fast track |

## Timeline

### Jun 2024: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2025-06-02, last confirmed 2025-10-23.
- SEC Form 8-K (accession 0001104659-25-101817): "GFH375 in China) was approved in China in June 2024, and the first patient was dosed in a Phase 1/2 study in July 2024." https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/tm2529362d1_8k.htm
- SEC Form 8-K (accession 0001104659-25-077659): "GFH375 in China) was approved in China in June 2024, and the first patient was dosed in a Phase 1/2 study in July 2024." https://www.sec.gov/Archives/edgar/data/1526119/000110465925077659/tm2523452d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-101817): "was approved in China in June 2024, and the first patient was dosed in a Phase 1/2 study in July 2024." https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/tm2529362d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-100537): "IND for VS-7375 (known as GFH375 in China) was approved in China in June 2024, and the first patient was dosed in a Phase 1/2 study in July 2024." https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/tm2529024d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-100537): "GenFleet's IND for VS-7375 (known as GFH375 in China) was approved in China in June 2024, and the first patient was dosed in a Phase 1/2 study in July 2024." https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/tm2529024d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-055286): "GenFleet's IND for VS-7375 (known as GFH375 in China) was approved in China in June 2024, and the first patient was dosed in a Phase 1/2 study in July 2024." https://www.sec.gov/Archives/edgar/data/1526119/000110465925055286/tm2516844d1_ex99-1.htm

### Jan 2025: FDA approval

- Status: completed, approved. Date confidence: month. Stage: 1/2.
- First seen 2026-03-04, last confirmed 2026-03-04.
- SEC Form 10-K (accession 0001104659-26-023444): "We exercised the GenFleet Option (defined herein) in January 2025, announced that our IND application for VS-7375 had been approved by the FDA in April 2025, and initiated a Phase 1/2a clinical trial in June 2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/vstm-20251231x10k.htm

### Jan 2025: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2026-03-04, last confirmed 2026-03-04.
- SEC Form 10-K (accession 0001104659-26-023444): "We exercised the GenFleet Option (defined herein) in January 2025, announced that our IND application for VS-7375 had been approved by the FDA in April 2025, and initiated a Phase 1/2a clinical trial in June 2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/vstm-20251231x10k.htm
- SEC Form 10-K (accession 0001104659-26-023444): "In January 2025, we exercised early the GenFleet Option for the lead compound VS-7375 and initiated a Phase 1/2a study in middle of 2025 in the U.S." https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/vstm-20251231x10k.htm

### Apr 2025: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2025-10-20, last confirmed 2025-10-20.
- SEC Form 8-K (accession 0001104659-25-100537): "The Company announced in April 2025 that the U.S. Investigational New Drug ("IND") application for VS-7375 was cleared and initiated a Phase 1/2a clinical trial in June 2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/tm2529024d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-100537): "Verastem announced in April 2025 that the U.S. Investigational New Drug (IND) application for VS-7375 was cleared and initiated a Phase 1/2a clinical trial in June 2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/tm2529024d1_ex99-1.htm

### mid-2025: trial start

- Status: scheduled. Date confidence: half. Stage: 1/2.
- First seen 2025-01-23, last confirmed 2025-06-02.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-055286): "Verastem announced in April 2025 that the U.S. Investigational New Drug (IND) application for VS-7375 was cleared and plans to initiate a Phase 1/2a clinical trial in mid-2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465925055286/tm2516844d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-052220): "Verastem announced in April 2025 that the U.S. Investigational New Drug (IND) application for VS-7375 was cleared and plans to initiate a Phase 1/2a clinical trial in mid-2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465925052220/tm2516049d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-026130): "Expect to initiate Phase 1/2a trial in U.S. in mid - 2025 VS - 7375/GFH375 KRAS G12D (ON/OFF) inhibitor Updated data from Phase 1 study by GenFleet in China expected by H12025" https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/tm259913d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-005460): "Anticipate filing U.S. IND for VS-7375 during Q1 2025 and initiate a Phase 1/2a study in mid-2025" https://www.sec.gov/Archives/edgar/data/1526119/000110465925005460/tm254144d1_ex99-1.htm
- SEC Form 10-K (accession 0001558370-25-003372): "We filed an IND application in the United States for VS-7375 during the first quarter of 2025 and expect to initiate a Phase 1/2a study in middle of 2025 in the United States." https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003372): "We filed an IND for VS-7375 in the United States in the first quarter of 2025 and plan to initiate a phase 1/2a trial in the United States in mid-2025." https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-003372): "In January 2025, we exercised early the GenFleet Option for the lead compound VS-7375 and expect to initiate a Phase 1/2a study in middle of 2025 in the United States." https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231x10k.htm

### Jun 2025: trial start

- Status: completed. Date confidence: month. Stage: 1/2. Indication: advanced KRAS G12D mutant solid tumors.
- First seen 2025-08-13, last confirmed 2026-10-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105923): "Verastem initiated VS-7375-101, a Phase 1/2a clinical trial, in June of 2025 in the U.S., with the potential to expand globally, that is evaluating the safety and efficacy of VS-7375 in patients with advanced KRAS G12D mutant solid tumors." https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-101817): "application for VS-7375 was cleared and initiated a Phase 1/2a clinical trial in June 2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/tm2529362d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-101817): "VS-7375 was cleared and initiated a Phase 1/2a clinical trial in June 2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/tm2529362d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-077659): "application for VS-7375 was cleared and initiated a Phase 1/2a clinical trial in June 2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465925077659/tm2523452d1_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-077659): "VS-7375 was cleared and initiated a Phase 1/2a clinical trial in June 2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465925077659/tm2523452d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-115687): "In June 2025, Verastem initiated TARGET-D 101, a Phase 1/2 dose escalation, dose expansion, and combination clinical trial evaluating the safety and efficacy of VS-7375 in patients with advanced" https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-010036): "Verastem initiated VS-7375-101, an international Phase 1/2 clinical trial, in June of 2025 in the U.S., that is evaluating the safety and efficacy of VS-7375 in patients with advanced KRAS G12D mutant solid tumors." https://www.sec.gov/Archives/edgar/data/1526119/000110465926010036/tm265057d1_ex99-1.htm
- SEC Form 10-K (accession 0001104659-26-023444): "In June 2025, we dosed the first patient in the monotherapy portion of VS-7375-101, the U.S. Phase 1/2 clinical trial evaluating VS-7375 in patients with advanced KRAS G12D mutant solid tumors, including PDAC, NSCLC, CRC and other KRAS G12D mutated solid tumors." https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/vstm-20251231x10k.htm

### October 22, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1/2.
- First seen 2025-11-04, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105923): "GenFleet also shared that the first patient has been dosed in a Phase 1b/2 study of GFH375 combined with cetuximab or chemotherapy for advanced solid tumors on October 22, 2025." https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm

### June 16, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2026-06-17, last confirmed 2026-11-05.
- SEC Form 8-K (accession 0001104659-26-074915): "On June 16, 2026, the Company also announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral" https://www.sec.gov/Archives/edgar/data/1526119/000110465926074915/tm2618108d1_8k.htm
- SEC Form 10-Q (accession 0001104659-26-123305): "In the first half of 2026, we initiated three Phase 2 registration-directed trials of VS-7375, our oral KRAS G12D (ON/OFF) inhibitor, dosing the first patients in TARGET-D 201 (PDAC) in June 2026, and both TARGET-D 202 (NSCLC) and TARGET-D 203 (CRC) in July 2026." https://www.sec.gov/Archives/edgar/data/1526119/000110465926123305/vstm-20260930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-115687): "On June 16, 2026, the first patient was dosed in the TARGET-D 201 trial." https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_ex99-2.htm

### late 2026: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-10-14, last confirmed 2026-10-14.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-115687): "Plan to report mature data from the TARGET-D 101 mCRC 900 mg combination with anti-EGFR cohort and initial data from the 600 mg VS-7375 plus cetuximab combination cohort in mPDAC by year-end 2026." https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_ex99-2.htm

### Q2 2027: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-10-14, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-115687): "Plan to report initial data from Phase 2 TARGET-D 201 2L PDAC in Q2 2027;" https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_ex99-2.htm
- SEC Form 10-Q (accession 0001104659-26-123305): "Ø We expect to report initial data from the TARGET-D 101 mPDAC cohort evaluating VS-7375 600 mg plus cetuximab in early 2027, with the data intended for presentation at a medical meeting." https://www.sec.gov/Archives/edgar/data/1526119/000110465926123305/vstm-20260930x10q.htm

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Pancreatic Ductal Adenocarcinoma (PDAC); G12D Mutated KRAS.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07644559 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." https://clinicaltrials.gov/study/NCT07644559

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Pancreatic Ductal Adenocarcinoma (PDAC); G12D Mutated KRAS.
- First seen 2026-08-07, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07644559 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." https://clinicaltrials.gov/study/NCT07644559
- Press release filed with the SEC (EX-99) (accession 0001104659-26-092216): "Expect to report topline primary endpoint of PFS by mid-2027" https://www.sec.gov/Archives/edgar/data/1526119/000110465926092216/tm2622452d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-092216): "Topline data expected in mid-2027." https://www.sec.gov/Archives/edgar/data/1526119/000110465926092216/tm2622452d1_ex99-1.htm

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07659782 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." https://clinicaltrials.gov/study/NCT07659782

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Non-Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07659782 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." https://clinicaltrials.gov/study/NCT07659782

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07659795 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." https://clinicaltrials.gov/study/NCT07659795

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07659795 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." https://clinicaltrials.gov/study/NCT07659795

## Same indication

- [ABBV-1480](https://sec-api.dev/pdufa/abbv-1480) (ABBV)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [Ivonescimab](https://sec-api.dev/pdufa/ivonescimab) (SMMT)
- [Iza-bren](https://sec-api.dev/pdufa/iza-bren) (BMY)
- [JDQ443](https://sec-api.dev/pdufa/jdq443) (NVS)
- [Amtagvi® (lifileucel)](https://sec-api.dev/pdufa/lifileucel) (IOVA)
- [N-803 + pembrolizumab](https://sec-api.dev/pdufa/n-803-pembrolizumab) (IBRX)
- [Petosemtamab](https://sec-api.dev/pdufa/petosemtamab) (GMAB)
- [Plinabulin](https://sec-api.dev/pdufa/plinabulin) (BYSI)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [Rilvegostomig](https://sec-api.dev/pdufa/rilvegostomig) (AZN)
- [Sigvotatug vedotin](https://sec-api.dev/pdufa/sigvotatug-vedotin) (PFE)
- [Telisotuzumab adizutecan](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) (ABBV)
- [XL092](https://sec-api.dev/pdufa/xl092) (EXEL)
- [Zanzalintinib](https://sec-api.dev/pdufa/zanzalintinib) (EXEL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vs-7375.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VS-7375 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vs-7375

```bibtex
@misc{secapidev_pdufa_vs_7375_20261116,
  title        = {VS-7375 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vs-7375}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vs_7375_20261116","title":"VS-7375 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vs-7375","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
